miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 28, 2026

Coca-Cola Reports First Quarter 2026 Results and Updates Full Year Guidance

View original at finance.yahoo.com
“Cash flow: Cash flow from operations and free cash flow (non-GAAP) were $2.0 billion and $1.8 billion, respectively.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • In the Philippines, single-serve Coca-Cola Zero Sugar packs grew double digits and delivered away-from-home volume growth

    60% confidence
  • EPS grew 18% to $0.91 in Q1 2026, with a 6-point currency tailwind; comparable EPS grew 18% to $0.86 with a 3-point currency tailwind

    60% confidence
  • Global unit case volume grew 3% in Q1 2026

    60% confidence
  • In North America, mini-can volume grew high single digits following the launch of single-serve mini-cans in convenience retail stores

    60% confidence
  • The company gained value share in total non-alcoholic ready-to-drink beverages in Q1 2026

    60% confidence
  • Operating margin was 35.0% versus 32.9% in the prior year; comparable operating margin was 34.5% versus 33.8% in the prior year

    60% confidence
  • Operating income grew 19%; comparable currency neutral operating income grew 12% in Q1 2026

    60% confidence
  • Sprite delivered double-digit volume growth in Brazil, supported by brand-led activations tied to Carnival and summer festivals

    60% confidence
  • Coca-Cola had a strong start to 2026 with performance reflecting unwavering focus on staying close to the consumer, executing locally and managing complexity

    60% confidence
  • Concentrate sales were 5 points ahead of unit case volume in Q1 2026, primarily due to six additional days in the quarter

    60% confidence
  • Coca-Cola set a Guinness World Record in Egypt for the most community meals served in one hour during Ramadan

    60% confidence
  • Cash flow from operations was $2.0 billion and free cash flow was $1.8 billion in Q1 2026

    60% confidence
  • Net revenues grew 12% to $12.5 billion in Q1 2026, and organic revenues grew 10%, driven by an 8% increase in concentrate sales and 2% growth in price/mix

    60% confidence
  • By leveraging key consumption occasions and local insights, the company increased weekly drinkers and gained value share globally during Q1 2026

    60% confidence
  • Comparable operating margin expansion was driven by organic revenue growth and lower operating expenses, partially offset by higher input costs and increased marketing investments

    60% confidence

Data points we hold from this source

The Coca-Cola Company · concentrate sales growth8 percent
The Coca-Cola Company · operating income growth19 percent
The Coca-Cola Company · free cash flow1.8 USD
The Coca-Cola Company · comparable eps0.86 USD
The Coca-Cola Company · comparable currency neutral operating income growth12 percent
The Coca-Cola Company · margin35.0 percent
The Coca-Cola Company · unit case volume growth3 percent
The Coca-Cola Company · comparable operating margin34.5 percent
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Coca-Cola Reports First Quarter 2026 Results and Updates Full Year Guidance — Source | Via News | es.VIA.NEWS